Pfizer will combine its off-patent drug business with Mylan
Pfizer, the world's largest drugmaker, plans to divest its off-patent drug business and combine it with generic-drug maker Mylan.
Under the terms of the agreement, which is structured as an all-stock deal, each Mylan share would be converted into one share of the new company.
Pfizer shareholders would own 57% of the combined new company and Mylan shareholders would own 43%, Mylan said. The Wall Street Journal first reported the news.
Pfizer's Dealmaker CEO Sharpens Cancer Focus With Mylan Plan
3 Things to Look For in Pfizer's Q2 Earnings Update
Mylan to combine with Pfizer's off-patent medicines unit
Pfizer Is Said to Plan a Deal for Its Off-Patent Drugs Unit
by Mukesh
mukeshathavale.manzi@gmail.com
Unnao rape survivor, critical after accident, wanted to shift case against BJP MLA to Delhi
Happy Birthday Sanjay Dutt: 5 Memorable Characters Played by the Actor